

117TH CONGRESS
2D SESSION

H. R. 8774

To require the Director of the National Institutes of Health to conduct an evaluation of menopause-related research (including gaps in research and knowledge regarding the causes, symptoms, and treatments for menopause), to develop a strategic plan to resolve gaps in knowledge and research, and identify topics in need of further research relating to potential treatments for menopause-related symptoms, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

SEPTEMBER 6, 2022

Mr. MCKINLEY (for himself and Mrs. AXNE) introduced the following bill;
which was referred to the Committee on Energy and Commerce

A BILL

To require the Director of the National Institutes of Health to conduct an evaluation of menopause-related research (including gaps in research and knowledge regarding the causes, symptoms, and treatments for menopause), to develop a strategic plan to resolve gaps in knowledge and research, and identify topics in need of further research relating to potential treatments for menopause-related symptoms, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Menopause Research
3 Act of 2022”.

4 **SEC. 2. EVALUATION OF MENOPAUSE-RELATED RESEARCH.**

5 (a) IN GENERAL.—The Director of the National In-
6 stitutes of Health shall—

7 (1) conduct an evaluation of—

8 (A) the results of completed menopause-re-
9 lated research, and research on mid-life wom-
10 en’s health;

11 (B) the status of ongoing menopause-re-
12 lated research, and research on mid-life wom-
13 en’s health; and

14 (C) any gaps in knowledge and research
15 on—

16 (i) treatments for menopause-related
17 symptoms; and

18 (ii) the safety and effectiveness of
19 treatments for menopause-related symp-
20 toms; and

21 (2) as part of such evaluation, identify the total
22 amount of funding allocated by the National Insti-
23 tutes of Health for the conduct or support of meno-
24 pause-related research, and research on mid-life
25 women’s health over the preceding 5 fiscal years.

1 (b) REPORT; STRATEGIC PLAN.—Not later than 180
 2 days after the date of enactment of this Act, the Director
 3 of the National Institutes of Health shall submit to the
 4 Congress—

5 (1) a report on the findings of such evaluation;
 6 and

7 (2) a strategic plan—

8 (A) to resolve the gaps in knowledge and
 9 research identified in the report; and

10 (B) to identify topics in need of further re-
 11 search relating to potential treatments for
 12 menopause-related symptoms.

13 **SEC. 3. MENOPAUSE-RELATED RESEARCH, AND RESEARCH**
 14 **ON MID-LIFE WOMEN'S HEALTH.**

15 (a) IN GENERAL.—The Secretary of Health and
 16 Human Services, acting through the Director of the Na-
 17 tional Institutes of Health, shall conduct or support meno-
 18 pause-related research, and research on mid-life women's
 19 health.

20 (b) AUTHORIZATION OF APPROPRIATIONS.—There is
 21 authorized to be appropriated to carry out this section
 22 \$100,000,000 for each of fiscal years 2023 and 2024.

○